For years, U.S. scientists and biotech companies have watched warily as China has made strides onto the global stage, overtaking them in research spending, patent applications, and clinical trials. To many observers, it has been a sign that the U.S. needs to urgently modernize a lumbering clinical trial and regulatory system. But now, a key…
Last year, a little-known Chinese startup took center stage at the American Society for Gene and Cell Therapy annual convention in New Orleans. Speaking before a sprawling conference hall for the presidential symposium, HuidaGene CEO Alvin Luk presented data from one of the world’s first trials to test if CRISPR gene editing could treat children…
I spent nearly two decades covering the biotech and pharma sector, first in Washington, D.C., and then in Beijing. My first story, published in 2007, covered the U.S. Food and Drug Administration’s decision to open its inaugural overseas office in China, a fast-emerging market I later covered for 12 years. In that time, I saw…
Allison covers what hot startups are getting up to, and who’s financing them. She is also co-host of the weekly biotech podcast, “The Readout Loud.” You can reach Allison on Signal at AllisonDeAngelis.01. Should the federal government try to slow — or even block — U.S. biotech deals that could benefit China? The question of…
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. The NIH’s foreign subaward crackdown is scrambling global collaborations, while China’s rapid ascent is reshaping drug development. Meanwhile, Wave Life Sciences sheds half its value on underwhelming obesity results. Also, breaking: I’m adopting a rogue…
WASHINGTON — AstraZeneca is set to strike a deal with the Trump administration to lower drug prices, people familiar with the matter told STAT. More details are expected to be shared at a 5 p.m. announcement with President Trump in the Oval Office. It comes a day after the company said it would invest $4.5…